Amylyx Pharmaceuticals Inc (AMLX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Sales | 0 | 87,371 | 380,786 | 22,230 | 285 |
| Cost of Goods | N/A | 124,633 | 25,441 | 2,993 | N/A |
| Gross Profit | N/A | -37,262 | 355,345 | 19,237 | 285 |
| Operating Expenses | 153,291 | 278,102 | 316,984 | 221,571 | 82,973 |
| Operating Income | -153,291 | -314,731 | 38,802 | -201,341 | -82,688 |
| Other Income | 8,602 | 12,595 | 15,495 | 3,740 | -5,243 |
| Pre-tax Income | -144,689 | -302,136 | 54,297 | -197,601 | -87,931 |
| Income Tax | 46 | -393 | 5,026 | 774 | N/A |
| Net Income Continuous | -144,735 | -301,743 | 49,271 | -198,375 | -87,931 |
| Net Income | $-144,735 | $-301,743 | $49,271 | $-198,375 | $-87,931 |
| EPS Basic Total Ops | -1.53 | -4.43 | 0.73 | -3.39 | -13.35 |
| EPS Basic Continuous Ops | -1.53 | -4.43 | 0.73 | -3.39 | -13.35 |
| EPS Diluted Total Ops | -1.53 | -4.43 | 0.70 | -3.39 | -13.35 |
| EPS Diluted Continuous Ops | -1.53 | -4.43 | 0.70 | -3.39 | -13.35 |
| EPS Diluted Before Non-Recurring Items | -1.53 | -2.37 | 0.70 | -3.39 | -13.35 |
| EBITDA(a) | $-158,292 | $-323,683 | $29,950 | $-202,910 | $-82,515 |